Supreme Court decisions in two cases pave way for IPR reforms

At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...
Read More
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a new...
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development

In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Researchers bring focus on science and medicine to California’s capital city

Health care issues are often so highly politicized that it’s easy to lose sight of the people behind the scenes, especially the millions of medical professionals that wake up each morning with a...
Read More
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches

A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in...
Read More
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New treatments could save $396 billion over 10 years, lead to better quality of life for migraine sufferers

A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the United States could save $396 billion in indirect costs over ten years and avoid 374...
Read More
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
ICYMI: Orphan drug development brings unique challenges

A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common...
Read More
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually

Sharing a portion of negotiated rebates at the pharmacy counter could save seniors in Medicare with diabetes more than $350 annually, according to a new analysis from IHS Markit. The data also show...
Read More
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements

May is World Trade Month, when we celebrate the many American companies exporting products around the world, and growing opportunities here in the U.S.
Read More
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D

Today, we are launching the “Let’s Talk About Medicare” advertising campaign focused on solutions to improve affordability and predictability for seniors in Medicare Part D. Similar to how the “Let’s...
Read More
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event

Yesterday, PhRMA president and CEO Stephen J. Ubl spoke at POLITICO’s “Deconstructing the Prescription Drug Supply Chain” event, discussing the incredible new era of medicine, medicine spending...
Read More
Event tomorrow: Making the biopharmaceutical supply chain work for patients

In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...
Read More